Clinical Trials Logo

Indolent B-cell Lymphoma clinical trials

View clinical trials related to Indolent B-cell Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00895661 Active, not recruiting - B-cell Lymphoma Clinical Trials

High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas. Rituximab (Rituxan) is a type of drug called an "antibody" that specifically targets B-cell lymphoma cells, and is approved by the FDA for the treatment of indolent B-cell non-hodgkin lymphomas and certain other types of non-hodgkin lymphomas. Standard doses currently used may not be achieving maximal efficacy. Higher doses have been shown to be safe in other clinical trials, and may offer superior efficacy to the current standard dose. This trial also employs intermittent maintenance doses of rituximab at the standard dose, which has been shown to prolong remissions and survival in patients with relapsed indolent B-cell lymphomas. This trial is designed to show that higher dose rituximab plus maintenance rituximab can achieve similarly good results to chemotherapy approaches, but without chemotherapy-related toxicity.